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Abstract
Several methods of treatment for hepatocellular carcinoma (HCC) are often used in combination for either palliation or
cure. We established a multidisciplinary treatment team (MDTT) at the San Francisco Veterans Affairs Medical Center in
November 2003 and assessed whether aggressive multimodality treatment strategies may affect survival. A prospective
database was established and follow-up information from patients with presumed HCC was collected up to November
2006. Information from the American College of Surgeons (ACS) cancer registry from January 2000 to November 2003
identified patients with HCC that were evaluated at the same institution prior to the establishment of the MDTT. The
establishment of a MDTT resulted in the doubling of patient referrals for treatment. Significantly more patients were
evaluated at earlier stages of disease and received either palliative or curative therapies. The overall survival (pB0.0001) and
length of follow-up (pB0.05) were significantly improved after the establishment of the MDTT. Stage-by-stage
comparisons indicate that aggressive multimodality therapy conferred significant survival advantage to patients with
American Joint Commission on Cancer (AJCC) stage II HCC (odds ratio 15.50, pB0.001). Multidisciplinary collaboration
and multimodality treatment approaches are important in the management of hepatocelluar carcinoma and improves
patient survival.
Key Words: Hepatocellular carcinoma, multidisciplinary communication, hepatectomy, palliative therapy
Introduction
Hepatocellular carcinoma (HCC) is the fifth most
prevalent cancer in the world. Development of
cirrhosis is the most important risk factor. In Asia
and Africa, chronic hepatitis B infection is the major
etiological factor for cirrhosis and HCC. In the USA,
the incidence of HCC is increasing with hepatitis C
virus (HCV) infection being responsible for most of
that increase [1,2].
The patient population of Veteran Affairs Medical
Centers (VAMC) is noteworthy in that the prevalence
of chronic HCV infection is much higher than in the
general population within the USA. Whereas, the
prevalence of HCV is 1.3% in the general public, it is
510% in veteran patients who utilize VAMC services
[3]. Risk factors for HCV infection in the veteran
population include history of intravenous drug use,
blood transfusions before 1992, combat medical
worker, tattoos, incarceration greater than 48 hours,
and greater than 15 lifetime sexual partners [4]. At
the San Francisco VAMC, as one of four resource
centers of VA’s National Hepatitis C Program, we
have an especially broad referral base of veteran
patients with HCV-related HCC. This affords us a
unique opportunity to investigate the factors that may
influence patient care for a growing population of
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patients who would develop HCV-related HCC in the
USA.
Multiple modalities are available to treat HCC.
Liver resection and liver transplantation are the two
potentially curative treatments. Ablative therapies
such as radiofrequency ablation (RFA), transarterial
embolization (TAE), transarterial chemoembolization
(TACE), and percutaneous ethanol injection (PEI)
have been shown to prolong survival [5]. Several
clinical advances may contribute to improving out-
comes in patients with HCC. These factors include
early detection of tumors through imaging, improved
morbidity and mortality of liver resection and trans-
plantation, and increased use of multimodality treat-
ments [68]. We believe that effective management of
HCC requires a multidisciplinary approach with
collaboration between hepatologists, oncologists,
radiologists, and surgeons. Therefore, we established
a multidisciplinary treatment team (MDTT) for
HCC at the San Francisco VAMC. Through this
team, there was fluid referral of patients between the
various disciplines and frequent joint conferences to
discuss individual patient cases. The aim of this study
was to evaluate the early results of implementing a
comprehensive disease-based multidisciplinary man-
agement team at a Veterans Affairs Medical Center.
Here we describe the results of our MDTT compared




A MDTT for patients with HCC was organized in
November 2003 at the San Francisco VAMC and a
prospective database was established and maintained.
Follow-up information from patients with presumed
HCC was collected and analyzed through November
2006 (36 months). Data for analysis included demo-
graphics, clinical history, histopathology, imaging
studies, laboratory values, operative findings, and
clinic follow-up information. For comparison, we
examined data from patients treated at our institution
during an earlier three-year time interval. The Amer-
ican College of Surgeons (ACS) cancer registry was
used to retrospectively identify patients evaluated for
HCC between November 2000 and November 2003
(36 months).
Patients
Patients were typically referred after undergoing
preliminary investigations at other VAMC affiliated
institutions. After referral, additional cross-sectional
imaging evaluation was conducted at the San Fran-
cisco VAMC in the form of computed tomography
(CT) and/or magnetic resonance imaging (MRI). The
authors’ approach to treatment and evaluation criteria
of tumor resectability, in general, followed the Na-
tional Comprehensive Cancer Network (NCCN)
clinical practice guidelines [9]. Decisions regarding
treatment modalities offered to patients (palliative
or curative) were made based on data from cross-
sectional imaging studies, analysis of local tumor-
related factors, social issues, and assessment of
underlying liver impairment. The vast majority of
HCC patients had some degree of underlying liver
dysfunction.
We quantified the extent of impaired liver function
using the Child-Pugh classification system to guide
treatment choices. We also used the Model of End-
stage Liver Disease (MELD) score since it correlated
well with Child-Pugh classification for predicting
perioperative mortality. A MELD score of B9 corre-
sponded to Child’s A classification, MELD 916
corresponded to Child’s B, and MELD 16 corre-
sponded to Child’s C [10]. Individual cases and
imaging studies were reviewed at a bimonthly multi-
disciplinary disease management conference attended
by surgeons, radiologists, medical oncologists, and
gastroenterologists.
Statistics
The Chi-squared, Fisher’s exact, and Mann-Whitney
tests were used where indicated to evaluate statistical
significance with the InStat 3.0 biostatistical program.
Statistical significance was considered when pB0.05.
This study was approved by the San Francisco VAMC
and University of California, San Francisco Commit-




A total of 121 patients with HCC were evaluated by
the surgical service between November 2003 and
November 2006. As expected from a VAMC popula-
tion, nearly all of these patients were men. Only one
patient was female. Their ages ranged between 48 and
88, with a median age of 58.
The etiology of HCC in this cohort was heavily
weighted toward viral hepatitis infection in nearly
80% of patients. The majority (n83, 69%), devel-
oped HCC from hepatitis C infection. In seven
patients (6%) the etiology was unknown and in 18
patients (15%) the cause of HCC was attributed to
alcohol consumption alone. Only six patients (5%)
had HCC caused by hepatitis B alone while another
six patients (5%) developed HCC in the presence of
both hepatitis B and hepatitis C (Figure 1A).
The stage of HCC at initial presentation was fairly
evenly distributed in the spectrum of early to ad-
vanced disease. About one-third of the patients
presented with small tumors less than 3 cm, another
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third had intermediate sized tumors 35 cm, and the
remaining third had advanced tumors 5 cm and larger
(Figure 1B). More than half of the patients had
solitary tumors while one-third had two to three
tumors. Seventeen patients (15%) had multifocal
disease with five or more tumors (Figure 1C).
We used MELD score as a surrogate indicator of
Child’s classification and degree of liver dysfunction.
Nearly half of our patients presented with preserved
liver function and low MELD scores (B9). Forty-nine
patients (42%) had intermediate MELD scores ran-
ging from 9 to 16, and only 10 patients (9%) had
advanced MELD scores (16) (Figure 1D).
Spectrum of treatments for hepatocellular carcinoma
(HCC)
Between November 2003 and November 2006, 121
patients with presumed HCC who fulfilled the study
criteria as outlined above were identified. Forty-four
patients (36%) had disease that was too advanced
to treat and were offered supportive care only.
The remaining 77 patients (64%) were offered either
palliative (n54) or curative (n23) treatments.
Patients who were not candidates for resection or
liver transplantation were treated with ablative
therapies such as RFA, TAE and PEI for palliation
(Figure 2). A substantial proportion of patients in
both the curative arm, nine of 23 (40%), and palliative
arm, 17 of 56 (30%), received treatment from two
modalities or more.
Fifty-four patients (45%) had treatments aimed
toward palliation. Twenty-four patients underwent
RFA, of which, 15 had a single RFA treatment session
(Figure 3). In two patients, percutaneous RFA of the
liver tumor(s) was done under CT guidance. The
majority (n22) were treated in the operating room
using either a laparoscopic or open approach. Treat-
ment by TAE (bland particle) of the hepatic artery
was done in 35 patients in the radiology suite. Of
these, 12 patients (34%) had two or more arterial
embolizations in separate sessions. Twenty-two pa-
tients had TAE alone. Finally, 15 patients received
Figure 1. Hepatocellular carcinoma (HCC) patient characteristics
evaluated by the multidisciplinary treatment team (MDTT) at the
San Francisco Veterans Affairs Medical Center. A total of 121
patients with HCC were evaluated by the MDTT between
November 2003 and November 2006. Graphs show the proportion
of patients with the given (A) etiological factor of HCC, (B) tumor
size (size of the largest tumor if more than one), (C) tumor number,
and (D) degree of liver dysfunction as estimated by MELD score.
Percentage of the total patient population is provided, followed by
the actual number of patients in parentheses.
Figure 2. Treatments received by hepatocellular carcinoma (HCC)
patients after establishment of the multidisciplinary treatment team
(MDTT). A total of 121 patients with HCC were evaluated by the
MDTT between November 2003 and November 2006. Forty-four
patients had disease that was too advanced for treatment and
received supportive care only. Treatments with curative intent
included liver resection and transplantation. Segmentectomies were
resections of three or fewer segments. Lobectomies included formal
right and left lobectomies as well as extended lobectomies. Ablative
therapies such as radiofrequency ablation (RFA), transarterial
embolization (TAE), and percutaneous ethanol injection (PEI)
were considered palliative. These treatments were either given alone
as a single modality (i.e. RFA or TAE) or in combination with other
modalities (i.e., RFA and PEI, RFA and TAE, TAE and PEI, or
RFA, TAE, and PEI).
Figure 3. Palliative treatments given by the multidisciplinary
treatment team (MDTT). The total number of patients who
underwent radiofrequency ablation (RFA), transarterial emboliza-
tion (TAE), and percutaneous ethanol injection (PEI) as palliative
therapies is listed. Whether the patient received a single treatment of
that modality or repeated treatments of the same modality is shown.
Patients treated with RFA all had only a single treatment with RFA.
In contrast, 12 of 35 (34%) of the patients treated with TAE had
two or more repeated treatments with TAE.
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PEI in conjunction with other treatment modalities
(RFA, TAE, or both). The range of treatments given
to these patients illustrates our multidisciplinary
multimodality treatment philosophy.
Twenty-three patients (19%) were treated with
curative intent. Six patients were transplanted and
17 underwent liver resections. The six liver transplant
patients were treated by RFA, TAE, or both to control
disease prior to definitive treatment. Among the 17
patients submitted to partial hepatectomy, eight
underwent anatomically based segmentectomies, five
had standard hemi-lobectomies, and four had ex-
tended lobectomies (Table I). The median follow-up
for resection patients was 19.3 months. At last follow-
up, nine patients were alive without disease (53%).
There were seven recurrences (41%) and four patients
(23%) died of recurrent disease. The median time to
recurrence was 15.8 months. There was one death
(post-operative day 50) from liver failure (patient
#17).
Pre- and post-multidisciplinary treatment team (MDTT)
outcomes
To determine whether establishment of the MDTT
improved HCC patient outcomes at the San Fran-
cisco VAMC, we compared our three-year prospective
database to information obtained from the ACS
cancer registry collected at our institution in the
previous three years. Comparing the two time periods
showed that the number of patients referred to the
surgical service for HCC treatment doubled from 62
to 112 after the implementation of the MDTT (Table
II). Through the improved referral system of the
MDTT, significantly more patients were evaluated
with earlier stages of HCC disease (pB0.0001). Prior
to the establishment of the MDTT, very few patients
evaluated had American Joint Committee on Cancer
(AJCC) stage 1 and 2 disease. In fact, 40% of the
patients presented to medical attention with stage four
metastatic HCC. However, in the three years after the
MDTT, this ratio reversed in that nearly 30% of the
patients evaluated were with stage 1 disease and
another 33% with stage 2 disease. As a result, a
greater proportion of patients received either curative
or palliative treatments for HCC (37% pre-MDTT
vs. 64% post-MDTT, pB0.0001).
Importantly, implementation of the MDTT im-
proved overall HCC patient survival. Only 13 of 62
patients (21%) survived during the pre-MDTT fol-
low-up period. In contrast, a significantly higher
percentage, 79 of 121 patients (65%), survived during
the post-MDTT follow-up period (pB0.0001, Table
II). This observation is especially remarkable con-
sidering that the median length of follow-up for HCC
patients was also significantly increased after the
establishment of the MDTT (4.5 months pre-
MDTT vs. 9.5 months post-MDTT, pB0.05). The
overall survival odds ratio post-MDTT was 7.10
compared to pre-MDTT (95% confidence interval,
3.4614.52; pB0.0001), indicating a substantial sur-
vival advantage for HCC patients at our institution
after the implementation of the MDTT (Table III).
Table I. Liver resections for curative intent of the multidisciplinary treatment team (MDTT).
Patient Operation Size (cm) Grade Margins Nodes Vascular invasion Recurrence Follow-up (months) Outcome
1 Segmentx 3.1 mod     7.9 AWOD
2 Segmentx 7.8 mod     4.8 AWOD
3 Segmentx 1.6* n/a n/a n/a n/a  13.0 AWOD
4 Hemihepx 8.0 well to mod     8.3 AWOD
5 Hemihepx 8.5 mod     0.3 AWOD
6 Hemihepx 11.5 mod     7.4 AWOD
7 Hemihepx 11.5 poor     3.1 AWOD
8 Ext. Hemihepx 3; mf mod to poor     26.6 AWOD
9 Ext. Hemihepx 8.0 mod to well     14.4 AWOD
10 Segmentx 3.5 mod     19.4 AWD
11 Segmentx 4.0 mod     4.9 AWD
12 Ext. Hemihepx 8.8 mod     24.5 AWD
13 Segmentx 2.0 mod     3.1 DOD
14 Segmentx 2.0 mod     3.7 DOD
15 Segmentx 4.1 mod to well     15.8 DOD
16 Hemihepx 1.5 well to mod     18.2 DOD
17 Ext. Hemihepx 6; mf mod to poor     2.8 DWOD**
Note: A total of 17 patients underwent curative liver resection. Operations performed were segmentectomy (segmentx), hemihepatectomy
(hemihepx), or extended hemihepatecomy (ext. hemihepx). Pathological findings included tumor size (mf denoted multifocal disease),
grade (differentiation classified as well, well to moderate, moderate, moderate to poor, and poor), resection margins (, positive resection
margins; , negative resection margins), nodes (, negative regional nodes), and vascular invasion (, present; , absent). Tumor
recurrence either occurred () or not () during the follow-up period calculated from the time of surgery. Survival outcomes at the time of
last follow-up were alive without disease (AWOD), alive with disease (AWD), death of disease (DOD), or death without disease (DWOD).
*Patient three had a 1.6 cm tumor on pre-operative tri-phasic liver computed tomography imaging but no tumor was found on the
pathological specimen.
**Patient 17 died of liver failure on post-operative day 50 without development of recurrent hepatocellular carcinoma.
408 T. T. Chang et al.
The comparison between the pre- and post-MDTT
databases showed that significantly more patients
presented with early stage HCC after the establish-
ment of the MDTT (Table II). In order to demon-
strate that the improvement in overall survival post-
MDTT was not only the increased number of early
disease stage patients, we performed a stage-by-stage
comparison for survival (Table III). There was no
statistically significant difference in survival for pa-
tients with stage I disease likely because there were too
few patients pre-MDTT (only three ) for statistical
analysis. However, comparing patients with stage II
disease, there was a remarkable survival advantage
after the implementation of the MDTT. The odds
ratio for survival post-MDTT for stage II patients was
15.50 (95% confidence interval 2.8285.09, pB
0.001) compared to pre-MDTT. This suggested that
the aggressive multimodality treatment strategy
adopted by the MDTT extended survival for stage II
patients. For stage III patients, a there was a trend
toward a survival advantage post-MDTT (odd ratio
2.19), but it was not statistically significant. Of note,
there was a statistically significant improvement in
survival for stage IV patients even though the number
of stage IV patients evaluated post-MDTT were very
few.
Discussion
HCC is an aggressive tumor that has a poor prognosis
if left untreated. The natural history of untreated
HCC has a median survival between one and eight
months and a five-year survival of 3% [11,12]. It’s a
disease that is increasing in incidence in the USA
likely associated with the increasing prevalence of
HCV infection. From 1993 to 1999, the incidence of
HCC among patient 65 years of age or older increased
from 14.2 per 100,000 to 18.1 per 100,000. In the
same period, HCV-related HCC increased from 11 to
21% [2]. Because the prevalence of chronic HCV
infection is much higher in veterans than in the
general population [3], these trends predict that
HCC incidence within the veteran patient population
will continue to increase significantly in the coming
years. Our medical center is one of only four national
HCV treatment referral centers within the VAMC
system. Accordingly, we have implemented a MDTT
to address the growing demands and special chal-
lenges of treating patients with HCC.
Since establishment of the MDTT, we have
adopted an aggressive, yet flexible, multidisciplinary
treatment strategy. Patients are offered transplanta-
tion or surgical resection whenever possible since
these remain the only curative modalities. We use
local regional ablative therapies as a bridge to
transplantation since pre-operative therapy with
TACE or RFA has been shown to provide good five-
year disease-free survival rates after liver transplant
[13,14]. There may also be a potential benefit to
tumor downstaging with locoregional therapies [15].
However, pre-transplant management remains con-
troversial because other studies did not document
improved survival with these pre-operative therapies
[16,17]. In our study, more than half of our patients
presented with solitary tumors B5 cm and within
Milan criteria for transplantation, however, many
patients were not transplant candidates due to on-
going psychosocial comorbidities.
As previously demonstrated and in our series, only
a fraction (19% in our series, 1530% in other series)
of patients with HCC are surgical candidates due to
advanced disease stage or inadequate liver reserve [5].
Unfortunately, the risk of disease recurrence following
resection remains high due to de novo tumor devel-
opment in the remnant cirrhotic liver. Recurrence
rates are estimated to be about 50% at three years
post-resection [18,19].
When patients were not candidates for resection or
liver transplantation because of performance status,
Table III. AJCC stage-by-stage and overall survival odds ratios after
establishment of the multidisciplinary treatment team (MDTT).
Survival odds ratio 95% confidence interval p-Value
Stage I 1.44 0.1217.92 NS
Stage II 15.50 2.8285.09 B0.001
Stage III 2.19 0.667.23 NS
Stage IV 21.00 1.83240.66 0.01
Overall 7.10 3.4614.52 B0.0001
Note: Survival odds ratios were calculated in comparison to before
the establishment of the MDTT by the Fisher’s exact test. NS
indicates not statistically significant.
Table II. Treatment and survival of patients before and after estab-









Total # of patients 62 121
AJCC stage*
I 3 (5%) 35 (29%)
II 11 (18%) 40 (33%)
IIIA 16 (26%) 34 (28%)
IIIB 3 (5%) 2 (2%)
IIIC 4 (6%) 4 (3%)
IV 25 (40%) 5 (4%)
Treatment
Not treated 39 (63%) 44 (36%)
Treated** 23 (37%) 77 (64%)
Palliative 19 (31%) 54 (45%)
Curative 4 (6%) 23 (19%)
Outcomes




Statistical significance by the *Chi-squared test, pB0.0001, **Fish-
er’s exact test, pB0.0001, or ***Mann-Whitney test, pB0.05.
Multidisciplinary treatment for HCC 409
severity of chronic liver disease, tumor-related factors,
or social reasons, they received a variety of ablative
therapies and close follow-up to control progression of
disease. Ablative therapies (RFA, TAE, or PEI) are
generally not curative and patients who receive them
as the initial primary treatment are at similar or
increased risk for tumor progression and recurrence
compared to resection patients [20]. In the absence of
effective medical therapies, it is our philosophy that an
aggressive multimodality treatment approach should
be pursued along with frequent surveillance imaging
to offer the best chance for extended survival.
In the present study, 3040% of patients treated
with curative or palliative intent were given two or
more treatment modalities. There is evidence that
combined modality treatment of HCC is efficacious
and improves survival. Treatment with TACE prior to
RFA is effective for tumors greater than 3 cm,
whereas RFA alone is recommended only for tumors
less than 2 cm [21]. While, in general, RFA is a
superior ablative therapy compared to PEI [22], there
are a few situations in which PEI is preferred. We use
PEI for small lesions (B3 cm) in the periphery of the
liver or those adjacent to portal structures. In these
anatomic locations, PEI offers effective tumor kill
with less radial tissue damage to important neighbor-
ing structures, such as the biliary tree, stomach,
duodenum, and colon which can be easily damaged
by other heat energy modalities, such as RFA. We also
use PEI in combination with TAE or TACE since the
two modalities together have demonstrated better
response rates compared to TACE alone [23,24].
The establishment of the MDTT accomplished
several important objectives that improved patient
outcomes. First of all, within a three- year period, we
were able to double the number of HCC referrals at
our institution. Second, we significantly increased the
number of patients evaluated for early stage HCC
(AJCC stage 1 and 2) who were amenable to either
curative or palliative treatments. This may be due to
improved screening, heightened awareness of clini-
cians to at risk individuals, and better communication
between the various disciplines involved in caring for
HCC patients. Identifying patients at an early disease
stage is important since more curative treatment
options are available according to the Barcelona
Clinic Liver Cancer System recommendations en-
dorsed by the American Association for the Study of
Liver Diseases (AASLD) [20]. Third, after imple-
mentation of the MDTT, with effective collaboration
between surgical, medical, and radiological special-
ties, more patients received either curative or palliative
treatments and many received combined modality
treatments. Finally, the efforts of the MDTT resulted
in significantly improved overall patient survival and
follow-up. The improvement in survival post-MDTT
was not only due to more patients evaluated at earlier
disease stages, since stage-by-stage comparisons de-
monstrated a remarkable survival advantage especially
for stage II patients after the establishment of the
MDTT. These results indicated that aggressive multi-
modality therapy increased survival for AJCC stage II
patients. Whether aggressive therapy may benefit
advanced stage HCC (stage III and IV) will likely
require further investigation.
In conclusion, HCC continues to be a challenging
clinical problem. This is especially true in the veteran
population in which the increased HCV prevalence
predicts that a higher number of veteran patients will
eventually develop HCC. We have shown that multi-
disciplinary collaboration and multimodality treat-
ment approaches are important in the treatment of
patients with HCC and lead to improved outcomes.
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